BioArctic will participate at the AAT-AD/PD Focus Meeting (Advances in Alzheimer Therapy – Alzheimer’s Disease/Parkinson’s Disease) on March 15-18, 2018 in Turin, Italy. At the conference there will be presentations of the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s disease, Parkinson’s disease and other related neurological disorders.
BioArctic’s mission is to improve the quality in life for patients with Alzheimer’s disease and Parkinson’s disease and is focused on developing disease modifying treatment based on the company’s antibodies. At the conference, BioArctic will present a poster entitled: Characterization of alpha-synuclein pathology progression in h[A30P]-alpha-synuclein transgenic mice following intramuscular injection of sonicated alpha-synuclein fibrils.
“We are looking forward to present BioArctic’s pre-clinical innovative data, to follow progression in the field and to interact with our global network,” said Gunilla Osswald, CEO of BioArctic.
For more information:
Gunilla Osswald, PhD, CEO
Telephone: + 46 8 695 69 30